Journal: bioRxiv

Article Title: Multivalent Targeting of Blood-Brain Barrier LRP1 for Neurovascular Recovery Therapy for Alzheimer’s Disease

doi: 10.1101/2024.05.06.592767

Figure Lengend Snippet: Quantitative representation of Aβ-positive areas ( a ) in brain coronal sections, identified through immune histochemistry (IHC), in both AD model and wild-type mice. Quantitative measurement of Aβ concentrations via ELISA in both AD and wild type mice of the whole-brain ( b ), its vasculature ( c ) and parenchyma ( d ). ELISA quantification of both brain vasculature and parenchyma ( e ) in AD and wild type mice of key proteins involved in trafficking (LRP1, PACSIN2, RAB5), metabolism (GLUT1), tight junction proteins (ZO-1, CLDN11), and other stress-related proteins (MBP, MAP-2, SRB1). For all analyzes (n = 3)

Article Snippet: Protein concentrations for various proteins, including LRP1 (NOVUS, NBP3-00449), PACSIN2 (Anruike, YX-160103M), RAB5 (abbexa, abx154598), GLUT1 (Anruike, YX-071242M), Claudin11 (Anruike, YX-031229M), ZO1 (Elabscience, E-EL-M1161), MBP (Elabscience, E-EL-M0805), MAP-2 (Anruike, YX-120118M), SRB1 (Anruike, ARK-756321A), and Aβ (invitrogen, KMB3441) were determined using ELISA kits following the manufacturer protocols.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: bioRxiv

Article Title: Multivalent Targeting of Blood-Brain Barrier LRP1 for Neurovascular Recovery Therapy for Alzheimer’s Disease

doi: 10.1101/2024.05.06.592767

Figure Lengend Snippet: Pearson correlation coefficients for the colocalization of LRP1 and BBB endothelial cells (CD31) pre- and post A 39 -POs administration ( a ). Analysis performed on images derived from three independent experiments, with 6-7 vessels studied per trial. Quantification of Aβ content in cerebrovascular endothelial cells and brain parenchyma ( b ) (n = 3, statistical analyzis performed using unpaired t-tests, **** p<0.0001). ELISA measurements ( c ) of vascular and parenchymal proteins in 12-month-old WT, Sham APP/PS1, and APP/PS1 post A 39 -POs treatment mice, encompassing LRP1, PACSIN2, RAB5, GLUT1, Claudin 11, ZO-1, MBP, MAP-2, and SRB1. STED microscopy ( d ) of LRP1 (white) on the vessel wall (green), indicative of active transcytosis. Post-treatment, Aβ deposits around the BBB (red) are cleared with notable Aβ signal presence within the vascular lumen. For (b) and (c), statistical significance determined using one-way ANOVA, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n ≥ 3.

Article Snippet: Protein concentrations for various proteins, including LRP1 (NOVUS, NBP3-00449), PACSIN2 (Anruike, YX-160103M), RAB5 (abbexa, abx154598), GLUT1 (Anruike, YX-071242M), Claudin11 (Anruike, YX-031229M), ZO1 (Elabscience, E-EL-M1161), MBP (Elabscience, E-EL-M0805), MAP-2 (Anruike, YX-120118M), SRB1 (Anruike, ARK-756321A), and Aβ (invitrogen, KMB3441) were determined using ELISA kits following the manufacturer protocols.

Techniques: Derivative Assay, Enzyme-linked Immunosorbent Assay, Microscopy

Journal: Diagnostics

Article Title: Serum Biomarkers for the Diagnosis of Glaucoma

doi: 10.3390/diagnostics11010020

Figure Lengend Snippet: Serum antibody levels measured by enzyme-linked immunosorbent assay (ELISA).

Article Snippet: The levels of anti-SSA antibody, anti-SSB antibody, HSP60, anti-α-fodrin antibody, myelin basic protein (MBP), and anti-nucleic acid (ANA) antibody were measured by enzyme-linked immunosorbent assay (ELISA) with the SSA IgG ELISA kit (KA0949, Abnova, Taoyuan City, Taiwan), SSB IgG ELISA kit (KA0950, Abnova), HSP60 ELISA kit (ADI-EKS-600, Enzo Life Sciences, Farmingdale, NY, USA), α-fodrin Ab IgG/IgA ELISA Kit (KA1087, Abnova), MBP ELISA kit (E-EL-H0161, Elabscience, Houston, TX, USA), and ANA Screen ELISA Kit (KA0939, Abnova), respectively, in accordance with the manufacturers’ protocols.

Techniques: Enzyme-linked Immunosorbent Assay, Control